HST
20
-4
CSCO
43
-8
DVA
56
-6
FAST
33
-11
FDX
19
-15
CCI
28
-14
CF
33
-17
APH
48
-8
ETR
46
-17
DLTR
31
-3
EA
28
-18
CNP
60
-11
ADSK
36
-4
CRM
17
-8
GOOGL
20
-15
DIS
49
-8
AME
35
-4
HRB
50
-7
AES
31
-8
EMC
1
-8
HST
20
-4
CSCO
43
-8
DVA
56
-6
FAST
33
-11
FDX
19
-15
CCI
28
-14
CF
33
-17
APH
48
-8
ETR
46
-17
DLTR
31
-3
EA
28
-18
CNP
60
-11
ADSK
36
-4
CRM
17
-8
GOOGL
20
-15
DIS
49
-8
AME
35
-4
HRB
50
-7
AES
31
-8
EMC
1
-8
Financhill
Back

Avalo Therapeutics 10K Form

Sell
7

AVTX
Avalo Therapeutics

Last Price:
$5.75
Seasonality Move:
-21.62%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AVTX News And Ratings

See the #1 stock for the next 7 days that we like better than AVTX

AVTX Financial Statistics

Sales & Book Value

Annual Sales: $441K
Cash Flow: $-15M
Price / Cash Flow: 0
Annual Sales: $12.70
Price / Book: 0.47

Profitability

EPS (TTM): -3523.98770
Net Income (TTM): $-35.1M
Gross Margin: $807K
Return on Equity: -375.96%
Return on Assets: -34.97%

Avalo Therapeutics Earnings Forecast

Key Avalo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for AVTX is 182.99%.
  • The Selling, General & Administrative Expenses for AVTX have been equal to 3,909.52% of Gross Profit Margin.
  • The Research & Development expenses have been 11,809.07% of Revenue.
  • The Net Earning history of AVTX is -7,965.76% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 7 years.

Avalo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AVTX
Website: avalotx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 19.96
Quick Ratio: 19.42

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AVTX Technical Analysis vs Fundamental Analysis

Sell
7
Avalo Therapeutics (AVTX) is a Sell

Is Avalo Therapeutics a Buy or a Sell?